Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Mike - “last full working week until Christmas”.....do you think the virus is going to take a few days off over the festive period....or that hospitals will close until their Boxing Day sales - it’s what clinical staff do they have shift covering throughout
Worthwhile reading the letter as it spells out quite clearly some of the headline issues / data gaps that must be reconciled. In a backdrop of huge political pressures, massive pharma commercial opportunity the regulators must resolve to uphold their duty of care to the world’s populations. With the threat of financial liability removed, together with what appears to be a low trials threshold to succeed, there is a danger that pharma are simply treating this as a modern day gold rush. I’m all for approval once I know that all aspects of the data evidence has been thoroughly reviewed and tested....
TLWilliams - your unfailing courtesy in responses to others together with the very level headed thinking behind points that you make in your posts make you a poster that I always enjoy reading. Even the way in which you deal with the trolls - or “nuisance posters” as you have previously called them - is carried off with style and dignity. Slightly old fashioned yet very welcome when it is all to easy to flame using all the social media tools.....carry on Sir!
Bruce you might find this article of interest
https://www.wired.com/story/the-astrazeneca-covid-vaccine-data-isnt-up-to-snuff/
The main positive that would come from a hostile bid is that it draws out other interested parties to put forward a counter offer - usually forces the value up for shareholder. However, would rather see us through the P3 armed with the golden data!
Parsley - a poster about a week ago explained that he had been involved in placing and that because of the scaling back (they estimated only a third fulfilled of requested amount) the IIs would have come in under the reporting thresholds unless already having a sizeable holding. Think he said that his application had been scaled back from £18m to £6m.
WinWin - sorry but think you’re wrong - if anything RM has always been over cautious - even listening to last interview with Interative he was careful not to over promise. PIs are like sponges for information - the way that Synairgen has designed and delivered their trial programmes has been first class and I expect P3 to be no different - as opposed to this govt’s logistics on testing, PPE, communications and the list goes on. This virus isn’t going away anytime soon - SNG will do its job
SCinv - you may well be interested in this article from the BMJ (just published) executive editor highlighting just how politics, scientists and others with conflicting interests have steered their own path for various personal gains - it pulls no punches. Thanks to Ted Danson on ADVFN for highlighting....
https://www.bmj.com/content/371/bmj.m4425
Lserankin - I believe that reviews can be posted online anytime ahead of the printed publication - the following extract is from The Lancet’s website:
"Articles in The Lancet journals are published online on a daily basis, ahead of subsequent print publication. Our standard embargo time is 6.30pm [US ET] or 23.30 [GMT], which corresponds to the time the article is published online. Occasionally, embargo times may vary.".
"Articles in The Lancet journals are published online on a daily basis, ahead of subsequent print publication. Our standard embargo time is 6.30pm [US ET] or 23.30 [GMT], which corresponds to the time the article is published online. Occasionally, embargo times may vary.".
Thanks to Dedalus who posted this on ADVFN Guild site - looks like it can be put online anytime with paper publication to follow.
CR109 - there was a period of guessing and speculation over when results would be due - the sp had been depressed through two large background sellers and in fact the Friday before results sp was still languishing in the 30s - many having bought in at much higher prices over the preceding couple of months. So in summary, frustration, lack of transparency over large sales, speculation rife, some arguments between posters........and then the Magic Monday RNS!
It is odd that after the success in the placing last week RM wasn’t subject to an investor interview - as the highly oversubscribed placing was significant and newsworthy, especially as the RNS contained a number of detailed releases on partnerships and P3 trial plans.
On reflection it suggests to me that we are due more news very soon which would provide even wider material to be covered off in interview with RM - am thinking (and hoping) that this coming week may be fruitful!